Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents

被引：69

作者：

Doherty, AM ^{[1
]}

机构：

[1] Inst Rech Jouveinal Parke Davis, F-94265 Fresnes, France

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 1999年 / 3卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(99)80068-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Preclinical and clinical studies of phosphodiesterase 4 inhibitors have shown that these agents may find utility in a wide range of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and various neurological disorders. The future of this class of drugs will depend upon the ability to demonstrate a reasonable safety margin against emesis and other typical phosphodieserase (PDE4) side effects, as well as in identification of the inflammatory disorder(s) most relevant to PDE4 inhibition.

引用

页码：466 / 473

页数：8

共 83 条

[1] ISOLATION OF A CDNA-ENCODING A HUMAN ROLIPRAM-SENSITIVE CYCLIC-AMP PHOSPHODIESTERASE (PDE IVD) [J].

BAECKER, PA ;

OBERNOLTE, R ;

BACH, C ;

YEE, C ;

SHELTON, ER .

GENE, 1994, 138 (1-2) :253-256

[2]

Banner Katharine H., 1996, Allergology International, V45, P125, DOI 10.2332/allergolint.45.125

[3] Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory [J].

Barad, M ;

Bourtchouladze, R ;

Winder, DG ;

Golan, H ;

Kandel, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :15020-15025

[4] Chronic obstructive pulmonary disease: new opportunities for drug development [J].

Barnes, PJ .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (10) :415-423

[5] The effect of the specific phosphodiesterase-IV-inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo [J].

Becker, AJ ;

Stief, CG ;

Meyer, M ;

Truss, MC ;

Forssmann, WG ;

Jonas, U .

JOURNAL OF UROLOGY, 1998, 160 (03) :920-925

[6] Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study [J].

Belayev, L ;

Busto, R ;

Ikeda, M ;

Rubin, LL ;

Kajiwara, A ;

Morgan, L ;

Ginsberg, MD .

BRAIN RESEARCH, 1998, 787 (02) :277-285

[7]

BIGLER A, 1998, J LEUKOCYTE BIOL, V63, P101

[8] Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4 [J].

Blease, K ;

Burke-Gaffney, A ;

Hellewell, PG .

BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (01) :229-237

[9] Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats [J].

Block, F ;

Tondar, A ;

Schmidt, W ;

Schwarz, M .

NEUROREPORT, 1997, 8 (17) :3829-3832

[10]

Bolger GB, 1997, BIOCHEM J, V328, P539

← 1 2 3 4 5 6 7 8 9 →